- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
- Altamira Therapeutics Provides Business Update
- Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
- Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
More ▼
Key statistics
On Friday, Altamira Therapeutics Ltd (CYTO:NAQ) closed at 1.28, 21.89% above the 52 week low of 1.05 set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.15 |
---|---|
High | 1.30 |
Low | 1.15 |
Bid | 1.22 |
Offer | 1.31 |
Previous close | 1.13 |
Average volume | 77.79k |
---|---|
Shares outstanding | 2.24m |
Free float | 2.22m |
P/E (TTM) | -- |
Market cap | 2.87m USD |
EPS (TTM) | -31.49 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼